Trial intelligence / Profile preview

CC-220 (Iberdomide) Monotherapy and Combination Therapy in Multiple Myeloma

NCT02773030Phase 2

Key facts

Status: Active, not recruiting
Start: Oct 2016
Primary completion: May 2024
Countries: 11
Sponsor: Celgene Corporation
Modality: Small Molecules

Drugs: iberdomide
Conditions: multiple myeloma (MM)

Overview

Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (11 cohorts), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicities at 28 days and Overall Response Rate at 22.11 weeks. Started Oct 2016; status: active, not recruiting.

Design

11 arms

Study design: Non-randomizedOpen-label

Cohort A: CC-220 Monotherapy - Part 1
CC-220 monotherapy dose escalation.
Cohort B: CC-220 + DEX - Part 1
CC-220 + Dexamethasone dose escalation.
Cohort D: CC-220 + DEX - Part 2
CC-220 + Dexamethasone dose expansion.
Cohort E: CC-220 + DEX + DARA - Part 1
CC-220 + Dexamethasone + Daratumumab dose escalation.
Cohort F: CC-220 + DEX + BTZ - Part 1
CC-220 + Dexamethasone + Bortezomib dose escalation.
Cohort G1: CC-220 + DEX + CFZ - Part 1
CC-220 + Dexamethasone + Carfilzomib dose escalation.

5 more in the full profile.

Who it enrols

Patients with relapsed/refractory or newly diagnosed multiple myeloma with measurable disease, adequate organ function, and ECOG PS 0-2. Excludes nonsecretory MM, plasma cell leukemia, amyloidosis, and peripheral neuropathy >= Grade 2.

Endpoints

Primary

Dose Limiting Toxicities28 days
Overall Response Rate22.11 weeks

Secondary

Treatment Related Adverse Events10.32 to 21.07 months
Adverse Events of Special Interest10.32 to 21.07 months
Very Good Partial Response Rate56.29 to 86.21 weeks
Overall Response Rate20.96 to 86.21 weeks
Time to Response4.14 to 19.14 weeks
Duration of Response36.80 to 161.33 weeks
Progression Free Survival20.96 to 86.21 weeks
Overall Survival74.20 to 91.54 weeks

Beyond the preview

Go deeper on NCT02773030.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02773030.